U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

ALK-positive anaplastic large cell lymphoma

MedGen UID:
233117
•Concept ID:
C1332079
•
Neoplastic Process
Synonyms: ALCL, ALK+; ALK+ ALCL; ALK+ anaplastic large cell lymphoma; ALK-Positive Anaplastic Large Cell Lymphoma; ALKoma; Anaplastic Large Cell Lymphoma, ALK-Positive; anaplastic large cell lymphoma, ALK-positive
Modes of inheritance:
Not genetically inherited
MedGen UID:
988794
•Concept ID:
CN307044
•
Finding
Source: Orphanet
clinical entity without genetic inheritance.
See: This record
Not genetically inherited (Orphanet)
 
Monarch Initiative: MONDO:0017602
Orphanet: ORPHA300895

Definition

A type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the expression of a protein called anaplastic lymphoma kinase (ALK). [from ORDO]

Professional guidelines

PubMed

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641
Should treatment of ALK-positive anaplastic large cell lymphoma be stratified according to minimal residual disease?
Rigaud C, Abbas R, Grand D, Minard-Colin V, Aladjidi N, Buchbinder N, Garnier N, Plat G, Couec ML, Duplan M, Lambilliotte A, Schmitt C, Leblanc T, Lamant L, Brugières L
Pediatr Blood Cancer 2021 Jun;68(6):e28982. Epub 2021 Mar 9 doi: 10.1002/pbc.28982. PMID: 33687135
Current management of peripheral T-cell lymphomas.
Gooptu M, Rhoades R, Pro B
Cancer Treat Res 2015;165:289-303. doi: 10.1007/978-3-319-13150-4_12. PMID: 25655615

Recent clinical studies

Etiology

Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V, Kuravi S, Ganguly S, Welch DR, Vivian CJ, Mushtaq MU, Hegde A, Iyer S, Behrang A, Ali SM, Madison RW, Venstrom JM, Jensen RA, McGuirk JP, Amin HM, Balusu R
ESMO Open 2021 Aug;6(4):100172. Epub 2021 Jul 7 doi: 10.1016/j.esmoop.2021.100172. PMID: 34242968Free PMC Article
ALK-positive anaplastic large cell lymphoma: an evolving story.
Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):248-59. doi: 10.2741/S438. PMID: 25961700
Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.
Damm-Welk C, Pillon M, Woessmann W, Mussolin L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):205-16. doi: 10.2741/S434. PMID: 25961696
ALK-positive cancer: still a growing entity.
Gorczyński A, Prełowska M, Adam P, Czapiewski P, Biernat W
Future Oncol 2014 Feb;10(2):305-21. doi: 10.2217/fon.13.184. PMID: 24490615
Allogeneic transplantation in T-cell lymphomas.
Schmitz N, Wu HS, Glass B
Semin Hematol 2014 Jan;51(1):67-72. Epub 2013 Nov 28 doi: 10.1053/j.seminhematol.2013.11.010. PMID: 24468318

Diagnosis

Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.
Mu W, Zhang M, Hu G, Han Y, Mao X, Chen C, Shen K, Dai Z, Zhu X, Zhou X, Huang L, Ao Q, Xiao M
Front Immunol 2023;14:1280007. Epub 2023 Dec 8 doi: 10.3389/fimmu.2023.1280007. PMID: 38143760Free PMC Article
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM
Eur J Cancer 2022 Mar;164:1-17. Epub 2022 Feb 1 doi: 10.1016/j.ejca.2021.12.029. PMID: 35121370
ALK-positive anaplastic large cell lymphoma: an evolving story.
Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):248-59. doi: 10.2741/S438. PMID: 25961700
Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.
Damm-Welk C, Pillon M, Woessmann W, Mussolin L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):205-16. doi: 10.2741/S434. PMID: 25961696

Therapy

Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
Brugières L, Cozic N, Houot R, Rigaud C, Sibon D, Arfi-Rouche J, Bories P, Cottereau AS, Delmer A, Ducassou S, Garnier N, Lamant L, Leruste A, Millot F, Moalla S, Morschhauser F, Nolla M, Pagnier A, Reguerre Y, Renaud L, Schmitt A, Simonin M, Verschuur A, Hoog Labouret N, Mahier Ait Oukhatar C, Vassal G
Eur J Cancer 2023 Sep;191:112984. Epub 2023 Jul 17 doi: 10.1016/j.ejca.2023.112984. PMID: 37549532
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V, Kuravi S, Ganguly S, Welch DR, Vivian CJ, Mushtaq MU, Hegde A, Iyer S, Behrang A, Ali SM, Madison RW, Venstrom JM, Jensen RA, McGuirk JP, Amin HM, Balusu R
ESMO Open 2021 Aug;6(4):100172. Epub 2021 Jul 7 doi: 10.1016/j.esmoop.2021.100172. PMID: 34242968Free PMC Article
KRCA-0008 suppresses ALK-positive anaplastic large-cell lymphoma growth.
Hwang J, Song I, Lee K, Kim HR, Hong EH, Hwang JS, Ahn SH, Lee J
Invest New Drugs 2020 Oct;38(5):1282-1291. Epub 2020 Jan 20 doi: 10.1007/s10637-020-00896-4. PMID: 31956933
Therapeutic options in peripheral T cell lymphoma.
Zhang Y, Xu W, Liu H, Li J
J Hematol Oncol 2016 Apr 12;9:37. doi: 10.1186/s13045-016-0267-0. PMID: 27071634Free PMC Article

Prognosis

Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
Rigaud C, Knörr F, Brugières L, Woessmann W
Best Pract Res Clin Haematol 2023 Mar;36(1):101444. Epub 2023 Feb 2 doi: 10.1016/j.beha.2023.101444. PMID: 36907641
Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma.
Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM
Eur J Cancer 2022 Mar;164:1-17. Epub 2022 Feb 1 doi: 10.1016/j.ejca.2021.12.029. PMID: 35121370
Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.
Choi JW, Lee Y, Kim H, Cho HY, Min SK, Kim YS
Am J Surg Pathol 2022 Feb 1;46(2):241-248. doi: 10.1097/PAS.0000000000001820. PMID: 34619707
Prognostic factors in paediatric anaplastic large cell lymphoma: role of ALK.
Damm-Welk C, Pillon M, Woessmann W, Mussolin L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):205-16. doi: 10.2741/S434. PMID: 25961696
Allogeneic transplantation in T-cell lymphomas.
Schmitz N, Wu HS, Glass B
Semin Hematol 2014 Jan;51(1):67-72. Epub 2013 Nov 28 doi: 10.1053/j.seminhematol.2013.11.010. PMID: 24468318

Clinical prediction guides

Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.
Mu W, Zhang M, Hu G, Han Y, Mao X, Chen C, Shen K, Dai Z, Zhu X, Zhou X, Huang L, Ao Q, Xiao M
Front Immunol 2023;14:1280007. Epub 2023 Dec 8 doi: 10.3389/fimmu.2023.1280007. PMID: 38143760Free PMC Article
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project.
Chiattone C, Civallero M, Fischer T, Miranda E, Manni M, Zing NPC, Pileri SA, Montoto S, Horwitz SM, Cabrera ME, De Souza CA, Nagler A, Luminari S, Ferreri AJM, Carson KR, Re A, Rigacci L, Nassi L, Stepanishyna Y, Federico M, Inghirami G
Hematol Oncol 2022 Dec;40(5):953-961. Epub 2022 Sep 15 doi: 10.1002/hon.3074. PMID: 36083035
Coexpression of MCT1 and MCT4 in ALK-positive Anaplastic Large Cell Lymphoma: Diagnostic and Therapeutic Implications.
Choi JW, Lee Y, Kim H, Cho HY, Min SK, Kim YS
Am J Surg Pathol 2022 Feb 1;46(2):241-248. doi: 10.1097/PAS.0000000000001820. PMID: 34619707
ALK-positive anaplastic large cell lymphoma: an evolving story.
Bonzheim I, Steinhilber J, Fend F, Lamant L, Quintanilla-Martinez L
Front Biosci (Schol Ed) 2015 Jun 1;7(2):248-59. doi: 10.2741/S438. PMID: 25961700
Molecular classification of T-cell lymphomas.
de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P
Crit Rev Oncol Hematol 2009 Nov;72(2):125-43. Epub 2009 Feb 23 doi: 10.1016/j.critrevonc.2009.01.002. PMID: 19233683

Recent systematic reviews

Diagnostic Challenge of Sarcomatoid Variant of ALK-Positive Anaplastic Large Cell Lymphoma: Case Report and Updated Systematic Literature Review.
Song F, Yu S, Jia M, Gao H, Sun PL
Int J Surg Pathol 2021 Sep;29(6):658-666. Epub 2021 Jan 11 doi: 10.1177/1066896920986967. PMID: 33427000

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...